News from contractpharma.comFollowNews from contractpharma.comAll of today’s top news stories from contractpharma.com. Get the full analysis behind how media bias impacts breaking news.Ground News has come across 162 headlines reported on by contractpharma.com during the past 3 months. contractpharma.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Is contractpharma.com credible or reliable? Our Factuality score answers both of those questions. When it comes to contractpharma.com, we’ve assigned a unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.Follow All of today’s top news stories from contractpharma.com. Get the full analysis behind how media bias impacts breaking news. Ground News has come across 162 headlines reported on by contractpharma.com during the past 3 months. contractpharma.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Is contractpharma.com credible or reliable? Our Factuality score answers both of those questions. When it comes to contractpharma.com, we’ve assigned a unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check. Information about contractpharma.comWhere is contractpharma.com located?contractpharma.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top contractpharma.com NewsVacaville · VacavilleCellular Origins, Fresenius Kabi sign development agreement for scalable automation of cell and gene therapy manufacturing100% Center coverage: 1 sourcesCellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs).See the StoryBreast Cancer · United StatesPI3K Inhibitor Wins FDA Approval for Advanced Breast Cancer100% Center coverage: 1 sourcesThe FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA-mutated, hormone receptor (HR)-positive/HER2-negative breast cancer that recurred during or after adjuvant endocrine therapy. Support for the approval came from the multicenter randomized INAVO120 trial, which showed that the addition of inavolisib to palbociclib […]See the StorySan Diego · San DiegoPoseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - PipelinereviewAllogeneic, TSCM-rich dual CAR-T for the treatment of hematologic malignancies, including multiple myeloma Nomination triggers $15 million milestone payment to Poseida, extending cash runway into early 2026 SAN DIEGO, CA, USA I October 17, 2024 I Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune, and …See the StoryLatest News StoriesTopics Most Covered by contractpharma.comAstraZenecaHealthMerckPfizerArtificial IntelligenceAstraZenecaHealthMerckSources Covering Similar TopicsGEN - Genetic Engineering and Biotechnology News…stocktitan.netbiopharmadive.compharmaceutical-technology.comPharmaphorumGEN - Genetic Engineering and Biotechnology News…stocktitan.netbiopharmadive.comSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.Breaking News Topics Related to contractpharma.comFranceGermanyCalifornia, United StatesMetropolitan City of MilanItalySan Diego CountyLombardy, ItalyMilan, LombardySan DiegoUnited States